These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14613376)

  • 21. Increases in Drug Spending Slow.
    State Legis; 2017 Apr; 43(4):6. PubMed ID: 28574682
    [No Abstract]   [Full Text] [Related]  

  • 22. Why Medicaid managed care is right for South Carolina.
    Simmons JW
    J S C Med Assoc; 2007 Oct; 103(8):238-9. PubMed ID: 18333592
    [No Abstract]   [Full Text] [Related]  

  • 23. Beware the increasing cost and number of orphan drugs.
    Silverman E
    Manag Care; 2013 Mar; 22(3):10-4. PubMed ID: 23610800
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members.
    Johnson RE; Goodman MJ; Hornbrook MC; Eldredge MB
    Health Serv Res; 1997 Apr; 32(1):103-22. PubMed ID: 9108807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pricing pain: relief in sight on drug costs?
    J Am Health Policy; 1992; 2(6):28-31. PubMed ID: 10122415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
    Fischer MA; Schneeweiss S; Avorn J; Solomon DH
    N Engl J Med; 2004 Nov; 351(21):2187-94. PubMed ID: 15548779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(6):1637-47. PubMed ID: 17102189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicaid HMOs exit markets. Shrinking pool of managed-care plans could mean lower reimbursement to provider.
    Saphir A; Rauber C
    Mod Healthc; 1999 Jun; 29(25):46, 48. PubMed ID: 10538598
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacy benefits in health maintenance organizations.
    Gold M; Joffe M; Kennedy TL; Tucker AM
    Health Aff (Millwood); 1989; 8(3):182-90. PubMed ID: 2793044
    [No Abstract]   [Full Text] [Related]  

  • 31. Highlights of the Medicare Prescription Drug Act.
    Conomikes GS
    J Okla State Med Assoc; 2005 Oct; 98(10):492-3. PubMed ID: 16296207
    [No Abstract]   [Full Text] [Related]  

  • 32. A compendium of managed care: past, present, and hints of the future--Part II.
    Friedenberg RM
    Radiology; 1998 Oct; 209(1):25-9. PubMed ID: 9769807
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.
    Hartung DM; Touchette DR; Ketchum KL; Haxby DG; Goldberg BW
    Clin Ther; 2004 Sep; 26(9):1518-32. PubMed ID: 15531015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of insurance type on prescription drug use and expenditures among elderly Medicare beneficiaries.
    Saleh SS; Weller W; Hannan E
    J Health Hum Serv Adm; 2007; 30(1):50-74. PubMed ID: 17557696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unaffordable insulin: patients pay the price.
    Conner F; Pfiester E; Elliott J; Slama-Chaudhry A
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):748. PubMed ID: 31535616
    [No Abstract]   [Full Text] [Related]  

  • 36. Competition and hospital costs.
    Friedman B; Bogue RJ
    JAMA; 1989 Aug; 262(5):616-7. PubMed ID: 2664234
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.
    Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
    Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit restrictions and gout treatment.
    Wang SM; Aranda GA; Gao S; Patel BV
    J Manag Care Pharm; 2013; 19(9):773-82. PubMed ID: 24156646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in Medicaid physician fees, 2003-2008.
    Zuckerman S; Williams AF; Stockley KE
    Health Aff (Millwood); 2009; 28(3):w510-9. PubMed ID: 19401290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The future of prescription drug cost-sharing: real progress or dropped opportunity?
    Fairman KA
    J Manag Care Pharm; 2008; 14(1):70-82. PubMed ID: 18240885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.